Social factors must be addressed to ensure the protection of community health
Healthcare payers and providers should consider social sustainability factors to ensure adequate community health protections and keep healthcare provision costs low.
Regulation
FDA expands EUA for Lilly-Incyte’s baricitinib as Covid-19 monotherapy
In the initial EUA, baricitinib was authorised for use only with remdesivir for the treatment...
Disappointing setback for Kyowa’s Nouryant in Parkinson’s disease treatment in Europe
EMA's CHMP proposed the rejection of Kyowa Kirin’s Nouryant for PD, thus delaying the drug's...
FDA approves GSK’s shingles vaccine for immunocompromised adults
The vaccine was first approved in the US in 2017 to prevent the disease in...
FDA approves AstraZeneca’s Bydureon BCise for paediatric type 2 diabetes
The once-weekly GLP-1 RA therapy is intended to be used as an adjunct to diet...
Fighting India’s ‘black fungus’ epidemic
What exactly is black fungus, and what can be done to combat the rise of this condition alongside Covid-19? Abi Millar finds out.
EMA committee recommends Moderna’s Covid-19 vaccine for adolescents
In a trial in adolescents, Spikevax stimulated a comparable antibody response to that observed in young adults.
Three drug distributors to pay $1.1bn to settle opioid claims by New York
McKesson, Cardinal Health and Amerisource Bergen Drug will be removed from the opioid lawsuit underway in the New York court.
Japan approves Roche-Regeneron’s Ronapreve for Covid-19 treatment
The approval is based on a Phase I trial of the antibody combination in Japanese participants and a global Phase III trial.
China approves AstraZeneca’s Imfinzi for small-cell lung cancer
The approval is based on data from the Phase III CASPIAN trial, where the Chinese cohort data was similar to the global findings.
Pfizer-BioNTech’s Covid-19 vaccine receives FDA priority review
The regulatory agency will decide on the vaccine’s approval for use in people aged 16 years and above in January next year.
